4820 Emperor Boulevard
689 articles with IQVIA
IQVIA Holdings Inc. announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of $1,100,000,000 in aggregate principal amount of senior notes due 2027
IQVIA Institute for Human Data Science Study: Record 59 New U.S. Drugs Launched in 2018, Success Rates Fall, R&D Trends Could Improve Productivity by 2023
A third of the new drugs identified as innovative therapies with novel mechanisms of action different from existing therapies
The IQVIA Institute for Human Data Science released a new report titled, “The Changing Landscape of Research and Development: Innovation, Drivers of Change, and Evolution of Clinical Trial Productivity.”
IQVIA Holdings Inc., will announce its first-quarter 2019 financial results before the market opens on Wednesday, May 1, 2019.
IQVIA™ (NYSE: IQV) today announced the expansion of Orchestrated Customer Engagement (OCE), IQVIA Technologies’ innovative commercial ecosystem, with the addition of Orchestrated Analytics for OCE, a powerful and flexible analytics solution that empowers life sciences companies to make smarter decisions by providing increased access to insights.
4/5/2019In January 2019, the U.S. Food and Drug Administration (FDA) updated a 2015 draft guidance on rare diseases.
IQVIA Holdings Inc. announced today the pricing of an underwritten, secondary public offering of 5,000,000 shares of its common stock by certain of its existing stockholders
IQVIA Holdings Inc. announced the launch of an underwritten, secondary public offering of 5,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC and investment funds associated with Bain Capital Investors, LLC, of which IQVIA intends to repurchase from the underwriter 1,000,000 shares.
First-of-its-kind patented privacy-preserving technology platform
IQVIA’s FluSTAR Online Dynamic Platform Helps Consumers Track Local Rates of Flu, Allergy and Asthma
IQVIA uses advanced analytics and innovative technology, to find medium-to-high rates of flu in multiple U.S. markets; highest levels in parts of Montana, Nebraska and Texas
The IQVIA Institute for Human Data Science published its Study on Global Medicine Spending. One of the findings is that total drug spending is expected to climb to more than $1.5 trillion by 2023. That’s a 50 percent increase from 2014.
A principal of private investment firm Burt-Hilliard Investments for more than a decade, Burt is a former executive officer of WellPoint, Inc.
It’s nice to be admired. Fortune released its list of the most respected companies across the globe and one pharma company made the top 50 list.
IQVIA Reports Fourth-Quarter and Full-Year 2018 Results, Issues First-Quarter and Full-Year 2019 Guidance
IQVIA Holdings Inc., a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, reported financial results for the quarter and year ended December 31, 2018.
IQVIA Introduces RIM Smart, the Industry’s First Fully Integrated, End-to-End Regulatory Information Management System
More than regulatory information management (RIM), IQVIA RIM Smart delivers intelligent, interconnected global management across the complete portfolio and regulatory lifecycle
IQVIA Biotech develops and delivers flexible, integrated clinical and commercial solutions designed specifically for early-stage life sciences companies
IQVIA Launches Next Generation Site Portal Technology Capabilities to Streamline Clinical Trial Communications
IQVIA continues to focus on improving efficiencies for sites and study teams with its latest cross-trial updates
IQVIA to Announce Fourth-Quarter and Full-Year 2018 Results and Issue 2019 Guidance on February 14, 2019
IQVIA Holdings Inc., will announce its fourth-quarter and full-year 2018 financial results and issue 2019 guidance before the market opens on Thursday, February 14, 2019.
Real-world evidence (RWE) or real-world data (RWD) relates to the collection of information about a drug’s safety and efficacy outside the structure of a clinical trial. Speaking yesterday, FDA Commissioner Scott Gottlieb laid out the FDA’s new framework for dealing with RWE and RWD.
IQVIA Holdings Inc. has once again been named to FORTUNE magazine’s “World’s Most Admired Companies” list. IQVIA received the distinction in FORTUNE’s Healthcare: Pharmacy and Other Services category with high marks in quality of management, effectiveness in conducting business globally, wise use of corporate assets, and value as a long-term investment.